Abstract
Metal-based compounds have been widely used for biomedical applications. Their unique characteristics make them attractive for both therapeutic and diagnostic purposes. However, numerous issues including toxicity, poor aqueous solubility, and unfavorable biodistribution hamper their widespread use. To overcome these drawbacks, the concept of metal-based prodrugs emerged. This field is particularly developed for applications in oncology. More precisely, tumor-associated stimuli (e.g., pH variation, redox activity, enzyme overexpression, etc.) have been exploited to trigger the selective delivery of active metal-based drugs to the tumor site. The main advances in this area are discussed in this Review.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
